ACM
ASMB icon

Accent Capital Management’s Assembly Biosciences ASMB Stock Holding History

Accent Capital Management’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.94K Buy
+142
New +$4.05K ﹤0.01% 297

Other funds holding ASMB

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Accent Capital Management's ASMB Position: Q1 2026 in Review

Accent Capital Management opened a new position in Assembly Biosciences (ASMB) in Q1 2026: 142 shares worth $3.94K. The stake represents ﹤0.01% of the portfolio and ranks #297 among its holdings.

75 funds tracked by Wall St. Rank hold ASMB as of Q1 2026.

  • Accent Capital Management held 142 shares of Assembly Biosciences worth $3.94K as of Q1 2026.
  • Assembly Biosciences was a new Accent Capital Management position in Q1 2026.
  • Assembly Biosciences made up ﹤0.01% of Accent Capital Management's portfolio in Q1 2026, its #297 holding.
  • 75 funds tracked by Wall St. Rank held Assembly Biosciences as of Q1 2026.

Based on Accent Capital Management's 13F filing for Q1 2026, filed 11 May 2026.